120 related articles for article (PubMed ID: 4296815)
1. [The influence of aldosterone and aldosterone antagonists on the pressor effect of synthetic Angiotensin II in primary chronic adrenal cortex insufficiency (M. Addison)].
Koczorek KR; Avenhaus H
Klin Wochenschr; 1966 Jul; 44(14):848-50. PubMed ID: 4296815
[No Abstract] [Full Text] [Related]
2. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
Luther JM; Gainer JV; Murphey LJ; Yu C; Vaughan DE; Morrow JD; Brown NJ
Hypertension; 2006 Dec; 48(6):1050-7. PubMed ID: 17043157
[TBL] [Abstract][Full Text] [Related]
3. Adrenal insufficiency.
Orth DN
Curr Ther Endocrinol Metab; 1994; 5():124-30. PubMed ID: 7704696
[No Abstract] [Full Text] [Related]
4. Relative inhibitory potency of five mineralocorticoid antagonists on aldosterone biosynthesis in vitro.
Netchitailo P; Delarue C; Perroteau I; Leboulenger F; Capron MH; Vaudry H
Biochem Pharmacol; 1985 Jan; 34(2):189-94. PubMed ID: 2981534
[TBL] [Abstract][Full Text] [Related]
5. [On the hydro-natriuretic effect of progesterone in patients with chronic adrenal cortex insufficiency treated with mineralo-corticoids].
Gritti FM; Agnoli GC; Descovich GC; Lodi A; Manetti R
Endocrinol Sci Cost; 1970 Jul; 31(3):175-94. PubMed ID: 5508495
[No Abstract] [Full Text] [Related]
6. Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms.
Cassis LA; Helton MJ; Howatt DA; King VL; Daugherty A
Br J Pharmacol; 2005 Feb; 144(3):443-8. PubMed ID: 15655500
[TBL] [Abstract][Full Text] [Related]
7. Relation of rates of excretion of urinary prostaglandin E metabolites to administration of angiotensin, aldosterone, and spironolactone in vivo.
Fretland DJ; Cammarata PS
Prostaglandins Leukot Med; 1984 Apr; 14(1):65-78. PubMed ID: 6587407
[TBL] [Abstract][Full Text] [Related]
8. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
[TBL] [Abstract][Full Text] [Related]
9. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
Huang BS; White RA; Ahmad M; Leenen FH
Hypertension; 2013 Sep; 62(3):564-71. PubMed ID: 23856493
[TBL] [Abstract][Full Text] [Related]
10. Effect of mineralocorticoid agonists and antagonists on binding of 3 H-aldosterone to adrenalectomized rat kidney plasma membranes.
Forte LR
Life Sci I; 1972 May; 11(10):461-73. PubMed ID: 4348285
[No Abstract] [Full Text] [Related]
11. Modulation of angiotensin II binding sites in neuronal cultures by mineralocorticoids.
Sumners C; Fregly MJ
Am J Physiol; 1989 Jan; 256(1 Pt 1):C121-9. PubMed ID: 2912130
[TBL] [Abstract][Full Text] [Related]
12. Adrenal corticosteroid replacement therapy.
Mortimer RH
Med J Aust; 1985 Oct; 143(8):350-2, 354. PubMed ID: 2995778
[No Abstract] [Full Text] [Related]
13. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure.
van den Berg DT; de Kloet ER; van Dijken HH; de Jong W
Endocrinology; 1990 Jan; 126(1):118-24. PubMed ID: 2293978
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes.
Harada E; Yoshimura M; Yasue H; Nakagawa O; Nakagawa M; Harada M; Mizuno Y; Nakayama M; Shimasaki Y; Ito T; Nakamura S; Kuwahara K; Saito Y; Nakao K; Ogawa H
Circulation; 2001 Jul; 104(2):137-9. PubMed ID: 11447075
[TBL] [Abstract][Full Text] [Related]
15. Central interactions between aldosterone and vasopressin on cardiovascular system.
Janiak P; Brody MJ
Am J Physiol; 1988 Jul; 255(1 Pt 2):R166-73. PubMed ID: 2839996
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Minas JN; Thorwald MA; Conte D; Vázquez-Medina JP; Nishiyama A; Ortiz RM
Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1178-88. PubMed ID: 26234762
[TBL] [Abstract][Full Text] [Related]
17. Effects of a spirolactone (SC-8109) in primary mineralocorticoid excess.
KISTLER H; FRAWLEY TF
J Clin Endocrinol Metab; 1960 Aug; 20():1158-67. PubMed ID: 14409470
[No Abstract] [Full Text] [Related]
18. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
[TBL] [Abstract][Full Text] [Related]
19. Further studies on the effects of intracrine and extracellular angiotensin II on the regulation of heart cell volume. On the influence of aldosterone and spironolactone.
De Mello WC; Gerena Y
Regul Pept; 2010 Dec; 165(2-3):200-5. PubMed ID: 20692299
[TBL] [Abstract][Full Text] [Related]
20. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
